Pharming Group N.V. (PHAR)
|Net Income (ttm)||40.29M|
|Trading Day||May 7|
|Day's Range||12.98 - 13.50|
|52-Week Range||12.24 - 21.99|
Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ("ADSs") have been admitted for listing on the Nasdaq Global Market ("Nasdaq") under the s...
Pharming Group Publicly Files Registration Statement with the U.S. SEC to Facilitate Listing of ADSs Representing Ord...
Pharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical...
Pharming Group N.V. has filed to go public with an IPO on the NASDAQ.
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated ... [Read more...]
Research and Development in Biotechnology
Sijmen de Vries
|Stock Exchange |
|Ticker Symbol |
In 2020, Pharming Group's revenue was 185.69 million, an increase of 9.86% compared to the previous year's 169.02 million. Earnings were 33.04 million, a decrease of -8.73%.